13F filer · CIK 1909617
QIMING U.S. VENTURES MANAGEMENT, LLC
BELLEVUE, WA · filing since Q4 2021 · last filing Nov 10, 2025
Reported value
$55.6M
+$32.0M vs prior
Positions
4
New / sold out
0 / 2
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $1.6M
Top-10 weight
100.0%
Biggest buys vs Q2 2025
No new or increased positions this quarter.
Biggest sells vs Q2 2025
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | VENTYX BIOSCIENCES INC | -412,225 | -100.0% | $-882.2K |
| Sold out | HILLEVAX INC | -372,615 | -100.0% | $-741.5K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2025
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | TOURMALINE BIO INCCOM | 741,691 | $35.5M | 63.76% |
| 2 | KORRO BIO INCCOM | 368,085 | $17.6M | 31.68% |
| 3 | JASPER THERAPEUTICS INCCOM NEW | 928,964 | $2.2M | 3.97% |
| 4 | KEZAR LIFE SCIENCES INCCOM NEW | 82,871 | $323.2K | 0.58% |